Plasma arginine/ADMA ratio as a sensitive risk marker for atherosclerosis: Shimane CoHRE study

Atherosclerosis

Volumn 239, Issue 1, 2015, Pages 61-66

  Notsu, Yoshitomo ^a   Yano, Shozo ^a   Shibata, Hiroshi ^a   Nagai, Atsushi ^a   Nabika, Toru ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Arginine; Asymmetric dimethylarginine (ADMA); Atherosclerosis; Intima media thickness (IMT)

Indexed keywords

ARGININE; N(G),N(G) DIMETHYLARGININE; BIOLOGICAL MARKER; N,N-DIMETHYLARGININE;

ADULT; AMINO ACID BLOOD LEVEL; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE COURSE; ECHOGRAPHY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; AGED; ANALOGS AND DERIVATIVES; BLOOD; BLOOD PRESSURE; BODY MASS; CAROTID ARTERY; COMMON CAROTID ARTERY; HYPERTENSION; JAPAN; MIDDLE AGED; PATHOPHYSIOLOGY; RISK FACTOR;

AGED; ARGININE; ATHEROSCLEROSIS; BIOMARKERS; BLOOD PRESSURE; BODY MASS INDEX; CAROTID ARTERIES; CAROTID ARTERY, COMMON; CAROTID INTIMA-MEDIA THICKNESS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; JAPAN; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84920718988     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.12.030     Document Type: Article

References (48)

1. Kielstein J.T., Donnerstag F., Gasper S., Menne J., Kielstein A., Martens-Lobenhoffer J., Scalera F., Cooke J.P., Fliser D., Bode-Boger S.M. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 2006, 37:2024-2029.
2. Böger R.H., Maas R., Schulze F., Schwedhelm E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality-an update on patient populations with a wide range of cardiovascular risk. Pharmacol. Res. 2009, 60(6):481-487.
3. Baylis C. Nitric oxide synthase derangements and hypertension in kidney disease. Curr. Opin. Nephrol. Hypertens. 2012, 21(1):1-6.
4. Zoccali C., Bode-Böger S., Mallamaci F., Benedetto F., Tripepi G., Malatino L., Cataliotti A., Bellanuova I., Fermo I., Frölich J., Böger R. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 22-29, 358(9299):2113-2117.
5. Nijveldt R.J., Teerlink T., Van Der Hoven B., Siroen M.P., Kuik D.J., Rauwerda J.A., van Leeuwen P.A. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin. Nutr. 2003 Feb, 22(1):23-30.
6. Krzyzanowska K., Mittermayer F., Wolzt M., Schernthaner G. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care 2007, 30(7):1834-1839.
7. Anderssohn M., Schwedhelm E., Lüneburg N., Vasan R.S., Böger R.H. Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitus. Diabetes Vasc. Dis. Res. 2010, 7:105-118.
8. Abedini S., Meinitzer A., Holme I., März W., Weihrauch G., Fellstrøm B., Jardine A., Holdaas H. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients. Kidney Int. 2010, 77(1):44-50.
9. Anderssohn M., Rosenberg M., Schwedhelm E., Zugck C., Lutz M., Lüneburg N., Frey N., Böger R.H. The L-Arginine-asymmetric dimethylarginine ratio is an independent predictor of mortality in dilated cardiomyopathy. J.Card. Fail. 2012, 18(12):904-911.
10. Böger R.H., Endres H.G., Schwedhelm E., Darius H., Atzler D., Lüneburg N., von Stritzky B., Maas R., Thiem U., Benndorf R.A., Diehm C. Asymmetric dimethylarginine as an independent risk marker for mortality in ambulatory patients with peripheral arterial disease. J.Intern. Med. 2011, 269:349-361.
11. Chirinos J.A., David R., Bralley J.A., Zea-Díaz H., Muñoz-Atahualpa E., Corrales-Medina F., Cuba-Bustinza C., Chirinos-Pacheco J., Medina-Lezama J. Endogenous nitric oxide synthase inhibitors, arterial hemodynamics, and subclinical vascular disease: the PREVENCION Study. Hypertension 2008, 52(6):1051-1059.
12. Furuki K., Adachi H., Matsuoka H., Enomoto M., Satoh A., Hino A., Hirai Y., Imaizumi T. Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery: an epidemiological study. Atherosclerosis 2007, 191(1):206-210.
13. Zsuga J., Torok J., Magyar M.T., Valikovics A., Gesztelyi R., Kéki S., Csiba L., Zsuga M., Bereczki D. Serum asymmetric dimethylarginine negatively correlates with intima-media thickness in early-onset atherosclerosis. Cerebrovasc. Dis. 2007, 23:388-394.
14. Kanazawa I., Yano S., Notsu Y., Yamaguchi T., Nabika T., Sugimoto T. Asymmetric dimethylarginine as a risk factor for cardiovascular disease in Japanese patients with type 2 diabetes mellitus. Clin. Endocrinol. (Oxf) 2011, 74(4):467-472.
15. Maas R., Xanthakis V., Polak J.F., Schwedhelm E., Sullivan L.M., Benndorf R., Schulze F., Vasan R.S., Wolf P.A., Böger R.H., Seshadri S. Association of the endogenous nitric oxide synthase inhibitor ADMA with carotid artery intimal media thickness in the Framingham Heart Study offspring cohort. Stroke 2009, 40(8):2715-2719.
16. Luiking Y.C., Ten Have G.A., Wolfe R.R., Deutz N.E. Arginine de novo and nitric oxide production in disease states. Am. J. Physiol. Endocrinol. Metab. 2012, 303(10):E1177-E1189.
17. Wijnands K.A., Hoeksema M.A., Meesters D.M., van den Akker N.M., Molin D.G., Briedé J.J., Ghosh M., Köhler S.E., van Zandvoort M.A., de Winther M.P., Buurman W.A., Lamers W.H., Poeze M. Arginase-1 deficiency regulates arginine concentrations and NOS2-mediated no production during endotoxemia. PLoS One 2014, 9(1):e86135.
18. Bode-Böger S.M., Scalera F., Ignarro L.J. The L-arginine paradox: importance of the L-arginine/asymmetrical dimethylarginine ratio. Pharmacol. Ther. 2007, 114(3):295-306.
19. Ellger B., Richir M.C., van Leeuwen P.A., Debaveye Y., Langouche L., Vanhorebeek I., Teerlink T., Van den Berghe G. Glycemic control modulates arginine and asymmetrical-dimethylarginine levels during critical illness by preserving dimethylarginine-dimethylaminohydrolase activity. Endocrinology 2008, 149(6):3148-3157.
20. Visser M., Vermeulen M.A., Richir M.C., Teerlink T., Houdijk A.P., Kostense P.J., Wisselink W., de Mol B.A., van Leeuwen P.A., Oudemans-van Straaten H.M. Imbalance of arginine and asymmetric dimethylarginine is associated with markers of circulatory failure, organ failure and mortality in shock patients. Br. J. Nutr. 2012, 107(10):1458-1465.
21. Staalsø J.M., Bergström A., Edsen T., Weikop P., Romner B., Olsen N.V. Low plasma arginine:asymmetric dimethyl arginine ratios predict mortality after intracranial aneurysm rupture. Stroke 2013, 44(5):1273-1281.
22. Notsu Y., Nabika T., Bokura H., Suyama Y., Kobayashi S., Yamaguchi S., Masuda J. Evaluation of asymmetric dimethylarginine and homocysteine in microangiopathy-related cerebral damage. Am. J. Hypertens. 2009, 22(3):257-262.
23. Hamano T., Fujisawa Y., Yamasaki M., Ito K., Nabika T., Shiwaku K. Contributions of social context to blood pressure: findings from a multilevel analysis of social capital and systolic blood pressure. Am. J. Hypertens. 2011, 24(6):643-646.
24. Hamano T., Kimura Y., Takeda M., Yamasaki M., Isomura M., Nabika T., Shiwaku K. Effect of environmental and lifestyle factors on hypertension: Shimane COHRE study. PLoS One 2012, 7(11):e49122. 10.1371/journal.pone.0049122.
25. Imai E., Horio M., Nitta K., Yamagata K., Iseki K., Hara S., Ura N., Kiyohara Y., Hirakata H., Watanabe T., Moriyama T., Ando Y., Inaguma D., Narita I., Iso H., Wakai K., Yasuda Y., Tsukamoto Y., Ito S., Makino H., Hishida A., Matsuo S. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin. Exp. Nephrol. 2007, 11:41-50.
26. Dobashi Y., Santa T., Nakagomi K., Imai K. An automated analyzer for methylated arginines in rat plasma by HPLC with post-column fluorescence reaction. Analyst 2002, 127:54-59.
27. Pencina M.J., D'Agostino R.B., D'Agostino R.B., Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat. Med. 2008, 27(2):157-172.
28. Polak J.F., Pencina M.J., Pencina K.M., O'Donnell C.J., Wolf P.A., D'Agostino R.B. Carotid-wall intima-media thickness and cardiovascular events. N.Engl. J. Med. 2011, 365:213-221.
29. Polak J.F., Szklo M., Kronmal R.A., Burke G.L., Shea S., Zavodni A.E., O'Leary D.H. The value of carotid artery plaque and intima-media thickness for incident cardiovascular disease: the multi-ethnic study of atherosclerosis. J.Am. Heart Assoc. 2013, 2(2):e000087.
30. Baldassarre D., Hamsten A., Veglia F., de Faire U., Humphries S.E., Smit A.J., Giral P., Kurl S., Rauramaa R., Mannarino E., Grossi E., Paoletti R., Tremoli E. Measurements of carotid intima-media thickness and of interadventitia common carotid diameter improve prediction of cardiovascular events: results of the improve (Carotid Intima Media Thickness [IMT] and IMT-progression as predictors of vascular events in a high risk European population) study. J.Am. Coll. Cardiol. 2012, 60(16):1489-1499. IMPROVE Study Group.
31. Böger R.H., Sullivan L.M., Schwedhelm E., Wang T.J., Maas R., Benjamin E.J., Schulze F., Xanthakis V., Benndorf R.A., Vasan R.S. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009, 119(12):1592-1600.
32. Pizzarelli F., Maas R., Dattolo P., Tripepi G., Michelassi S., D'Arrigo G., Mieth M., Bandinelli S., Ferrucci L., Zoccali C. Asymmetric dimethylarginine predicts survival in the elderly. Age (Dordr) 2013, 35(6):2465-2475.
33. Zoccali C., Benedetto F.A., Maas R., Mallamaci F., Tripepi G., Malatino L.S., Böger R., CREED Investigators Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J.Am. Soc. Nephrol. 2002, 13(2):490-496.
34. Nanayakkara P.W., Teerlink T., Stehouwer C.D., Allajar D., Spijkerman A., Schalkwijk C., ter Wee P.M., van Guldener C. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney Int. 2005, 68(5):2230-2236.
35. Cobanoglu A.K., Gungor O., Kircelli F., Altunel E., Asci G., Ozbek S.S., Toz H., Ok E. Role of asymmetric dimethylarginine in the progression of carotid atherosclerosis in renal transplant patients. Int. Urol. Nephrol. 2013, 45(5):1463-1469.
36. Xia W., Shao Y., Wang Y., Wang X., Chi Y. Asymmetric dimethylarginine and carotid atherosclerosis in Type 2 diabetes mellitus. J.Endocrinol. Invest. 2012, 35(9):824-827.
37. Serg M., Kampus P., Kals J., Zagura M., Muda P., Tuomainen T.P., Zilmer K., Salum E., Zilmer M., Eha J. Association between asymmetric dimethylarginine and indices of vascular function in patients with essential hypertension. Blood Press. 2011, 20(2):111-116.
38. Furuki K., Adachi H., Enomoto M., Otsuka M., Fukami A., Kumagae S., Matsuoka H., Nanjo Y., Kakuma T., Imaizumi T. Plasma level of asymmetric dimethylarginine (ADMA) as a predictor of carotid intima-media thickness progression: six-year prospective study using carotid ultrasonography. Hypertens. Res. 2008, 31(6):1185-1189.
39. Bai Y., Sun L., Du L., Zhang T., Xin W., Lan X., Du G. Association of circulating levels of asymmetric dimethylarginine (ADMA) with carotid intima-media thickness: evidence from 6168 participants. Ageing Res. Rev. 2013, 12(2):699-707.
40. Masuda H., Goto M., Tamaoki S., Azuma H. Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxan-induced hyperglycemia. Br. J. Pharmacol. 1999, 126(1):211-218.
41. Cardounel A.J., Zweier J.L. Endogenous methylarginines regulate neuronal nitric-oxide synthase and prevent excitotoxic injury. J.Biol. Chem. 2002, 277(37):33995-34002.
42. Cardounel A.J., Cui H., Samouilov A., Johnson W., Kearns P., Tsai A.L., Berka V., Zweier J.L. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J.Biol. Chem. 2007, 282(2):879-887.
43. Teerlink T., Luo Z., Palm F., Wilcox C.S. Cellular ADMA: regulation and action. Pharmacol. Res. 2009, 60(6):448-460.
44. Jaenecke I., Boissel J.P., Lemke M., Rupp J., Gasnier B., Closs E.I. Achimera carrying the functional domain of the orphan protein SLC7A14 in the backbone of SLC7A2 mediates trans-stimulated arginine transport. J.Biol. Chem. 2012, 287(36):30853-30860.
45. Lind L., Larsson A., Teerlink T. L-Arginine is related to endothelium-dependent vasodilation in resistance and conduit arteries in divergent ways-The Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Atherosclerosis 2009, 203(2):544-549.
46. Nicholls S.J., Wang Z., Koeth R., Levison B., DelFraino B., Dzavik V., Griffith O.W., Hathaway D., Panza J.A., Nissen S.E., Hochman J.S., Hazen S.L. Metabolic profiling of arginine and nitric oxide pathways predicts hemodynamic abnormalities and mortality in patients with cardiogenic shock after acute myocardial infarction. Circulation 2007, 116(20):2315-2324.
47. Schlaich M.P., Parnell M.M., Ahlers B.A., Finch S., Marshall T., Zhang W.Z., Kaye D.M. Impaired L-arginine transport and endothelial function in hypertensive and genetically predisposed normotensive subjects. Circulation 2004, 110(24):3680-3686.
48. Davids M., Teerlink T. Plasma concentrations of arginine and asymmetric dimethylarginine do not reflect their intracellular concentrations in peripheral blood mononuclear cells. Metabolism 2013, 62(10):1455-1461.